OncoSil Medical Ltd: IDE Approval from the U.S. Food and Drug Administration
U S Food and Drug Administration | August 02, 2016
OncoSil Medical Ltd (ASX:OSL) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). The company will now initiate a pivotal clinical investigation for OncoSil™ for the treatment of eligible subjects with pancreatic cancer.